Temozolomide as Maintenance Therapy in Small Cell Lung Cancer

Summary

Temozolomide, a nonclassic oral alkylating agent, may delay progression in sequence with chemotherapy. This phase II trial was designed to evaluate the role of Temozolomide following 4 or 6 cycles of first-line treatment in patients with newly diagnosed SCLC.

Timeline

Start

2013-01

Primary completion

2016-02

Completion

2016-06

Drugs

Indications